159 related articles for article (PubMed ID: 33446608)
1. Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trial.
Wittermans E; Vestjens SMT; Spoorenberg SMC; Blok WL; Grutters JC; Janssen R; Rijkers GT; Smeenk FWJM; Voorn GP; van de Garde EMW; Bos WJW; ;
Eur Respir J; 2021 Aug; 58(2):. PubMed ID: 33446608
[TBL] [Abstract][Full Text] [Related]
2. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial.
Meijvis SC; Hardeman H; Remmelts HH; Heijligenberg R; Rijkers GT; van Velzen-Blad H; Voorn GP; van de Garde EM; Endeman H; Grutters JC; Bos WJ; Biesma DH
Lancet; 2011 Jun; 377(9782):2023-30. PubMed ID: 21636122
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil count, lymphocyte count and neutrophil-to-lymphocyte ratio in relation to response to adjunctive dexamethasone treatment in community-acquired pneumonia.
Wittermans E; van de Garde EM; Voorn GP; Aldenkamp AF; Janssen R; Grutters JC; Bos WJW;
Eur J Intern Med; 2022 Feb; 96():102-108. PubMed ID: 34782191
[TBL] [Abstract][Full Text] [Related]
4. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.
Blum CA; Nigro N; Briel M; Schuetz P; Ullmer E; Suter-Widmer I; Winzeler B; Bingisser R; Elsaesser H; Drozdov D; Arici B; Urwyler SA; Refardt J; Tarr P; Wirz S; Thomann R; Baumgartner C; Duplain H; Burki D; Zimmerli W; Rodondi N; Mueller B; Christ-Crain M
Lancet; 2015 Apr; 385(9977):1511-8. PubMed ID: 25608756
[TBL] [Abstract][Full Text] [Related]
5. The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial.
Viasus D; Garcia-Vidal C; Simonetti AF; Dorca J; Llopis F; Mestre M; Morandeira-Rego F; Carratalà J
BMJ Open; 2015 Jan; 5(1):e006251. PubMed ID: 25564143
[TBL] [Abstract][Full Text] [Related]
6. Benefit of adjunct corticosteroids for community-acquired pneumonia in diabetic patients.
Popovic M; Blum CA; Nigro N; Mueller B; Schuetz P; Christ-Crain M
Diabetologia; 2016 Dec; 59(12):2552-2560. PubMed ID: 27614658
[TBL] [Abstract][Full Text] [Related]
7. Effect of adjunctive single high-dose vitamin D
Slow S; Epton M; Storer M; Thiessen R; Lim S; Wong J; Chin P; Tovaranonte P; Pearson J; Chambers ST; Murdoch DR;
Sci Rep; 2018 Sep; 8(1):13829. PubMed ID: 30218062
[TBL] [Abstract][Full Text] [Related]
8. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.
Laterre PF; Colin G; Dequin PF; Dugernier T; Boulain T; Azeredo da Silveira S; Lajaunias F; Perez A; François B
Lancet Infect Dis; 2019 Jun; 19(6):620-630. PubMed ID: 31056427
[TBL] [Abstract][Full Text] [Related]
9. Multicenter Osteopathic Pneumonia Study in the Elderly: Subgroup Analysis on Hospital Length of Stay, Ventilator-Dependent Respiratory Failure Rate, and In-hospital Mortality Rate.
Noll DR; Degenhardt BF; Johnson JC
J Am Osteopath Assoc; 2016 Sep; 116(9):574-87. PubMed ID: 27571294
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).
Barrera CM; Mykietiuk A; Metev H; Nitu MF; Karimjee N; Doreski PA; Mitha I; Tanaseanu CM; Molina JM; Antonovsky Y; Van Rensburg DJ; Rowe BH; Flores-Figueroa J; Rewerska B; Clark K; Keedy K; Sheets A; Scott D; Horwith G; Das AF; Jamieson B; Fernandes P; Oldach D;
Lancet Infect Dis; 2016 Apr; 16(4):421-30. PubMed ID: 26852726
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial.
Snijders D; Daniels JM; de Graaff CS; van der Werf TS; Boersma WG
Am J Respir Crit Care Med; 2010 May; 181(9):975-82. PubMed ID: 20133929
[TBL] [Abstract][Full Text] [Related]
12. Procalcitonin, a valuable biomarker assisting clinical decision-making in the management of community-acquired pneumonia.
Lindstrom ST; Wong EK
Intern Med J; 2014 Apr; 44(4):390-7. PubMed ID: 24528892
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia: a protocol for a randomIsed controlled Trial (CAP-IT).
Lyttle MD; Bielicki JA; Barratt S; Dunn D; Finn A; Harper L; Jackson P; Powell CVE; Roland D; Stohr W; Sturgeon K; Wan M; Little P; Faust SN; Robotham J; Hay AD; Gibb DM; Sharland M;
BMJ Open; 2019 May; 9(5):e029875. PubMed ID: 31123008
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and significance of various scores for pneumonia severity in the management of patients with community-acquired pneumonia in China.
Yang Y; Xu F; Shi LY; Diao R; Cheng YS; Chen XY; Jing JY; Wang XD; Shen HH
Chin Med J (Engl); 2012 Feb; 125(4):639-45. PubMed ID: 22490488
[TBL] [Abstract][Full Text] [Related]
15. Empirical prescribing of penicillin G/V reduces risk of readmission of hospitalized patients with community-acquired pneumonia in Norway: a retrospective observational study.
Høgli JU; Garcia BH; Svendsen K; Skogen V; Småbrekke L
BMC Pulm Med; 2020 Jun; 20(1):169. PubMed ID: 32539706
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers define the clinical response to dexamethasone in community-acquired pneumonia.
Remmelts HH; Meijvis SC; Heijligenberg R; Rijkers GT; Oosterheert JJ; Bos WJ; Endeman H; Grutters JC; Hoepelman AI; Biesma DH
J Infect; 2012 Jul; 65(1):25-31. PubMed ID: 22410382
[TBL] [Abstract][Full Text] [Related]
17. Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study.
Frei CR; Jaso TC; Mortensen EM; Restrepo MI; Raut MK; Oramasionwu CU; Ruiz AD; Makos BR; Ruiz JL; Attridge RT; Mody SH; Fisher A; Schein JR
Curr Med Res Opin; 2009 Apr; 25(4):859-68. PubMed ID: 19231913
[TBL] [Abstract][Full Text] [Related]
18. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial.
Torres A; Sibila O; Ferrer M; Polverino E; Menendez R; Mensa J; Gabarrús A; Sellarés J; Restrepo MI; Anzueto A; Niederman MS; Agustí C
JAMA; 2015 Feb; 313(7):677-86. PubMed ID: 25688779
[TBL] [Abstract][Full Text] [Related]
19. XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial.
Song Y; Yao C; Yao Y; Han H; Zhao X; Yu K; Liu L; Xu Y; Liu Z; Zhou Q; Wang Y; Ma Z; Zheng Y; Wu D; Tang Z; Zhang M; Pan S; Chai Y; Song Y; Zhang J; Pan L; Liu Y; Yu H; Yu X; Zhang H; Wang X; Du Z; Wan X; Tang Y; Tian Y; Zhu Y; Wang H; Yan X; Liu Z; Zhang B; Zhong N; Shang H; Bai C
Crit Care Med; 2019 Sep; 47(9):e735-e743. PubMed ID: 31162191
[TBL] [Abstract][Full Text] [Related]
20. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial.
Carratalà J; Garcia-Vidal C; Ortega L; Fernández-Sabé N; Clemente M; Albero G; López M; Castellsagué X; Dorca J; Verdaguer R; Martínez-Montauti J; Manresa F; Gudiol F
Arch Intern Med; 2012 Jun; 172(12):922-8. PubMed ID: 22732747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
